GetWell Secures Tens of Millions in Series A Funding from Jianyin Zhongmin Healthcare Kunshan Fund to Build a Precision Health Management Ecosystem

VCBeat (WeChat: vcbeat)It is reported that recently, JiaDong Health, a precision exercise and health technology company (getwell) announced that it has secured a strategic investment from the CCB Zhongmin Medical Kunshan Fund in its latest round of financing, completing tens of millionsAround of financing. Jiadong Health is a technology company specializing in precision exercise and health management, dedicated to the research and application of metabolic monitoring and artificial intelligence technologies in the field of exercise and health.

"This round of financing is primarily intended to support the company's next phase of business expansion, including the establishment of a marketing network, scaling up operational capabilities, brand building, and obtaining medical certifications and regulatory approvals."

Currently, Jiadong Health’s product portfolio includes:

World’s First Ultra-Portable Optical Device for Cardiopulmonary Assessment of Aerobic Capacity

Aerobic Capacity: The Fifth Vital SignAs a broad-spectrum biomarker, aerobic capacity is recognized by the international medical community as the gold standard for predicting future health risks and prescribing exercise regimens. Historically, assessing aerobic capacity was confined to large hospitals or elite sports laboratories, involving complex procedures and uncomfortable user experiences. JiaDong Health replaces traditional equipment with ultra-portable technology to professionally assess aerobic capacity and metabolic status, enabling users to enjoy convenient and comprehensive health evaluations in just 15 minutes.

Personal Precision Exercise Monitoring Device

The personal-end system comprises the T1 muscle oxygen monitoring device, the H2 heart rate monitoring device, and a mobile application. It enables real-time monitoring of exercise status and changes in muscle oxygen levels, provides precise guidance for exercise training, effectively enhances workout outcomes, and intelligently matches exercise plans based on the user’s health status to achieve personalized and precise exercise management.

Precision Exercise and Health Management Platform

The platform comprises an intelligent, personalized precision exercise management system integrating “muscle oxygen + heart rate,” a precision nutrition management system, an enterprise/individual membership management system, and an AI health engine. By matching data on the needs, physiological indicators, and health status of diverse populations, the platform delivers accurate, customized exercise and nutrition management solutions.

Jiadong Health’s core innovative products possess independent intellectual property rights and are not only leading exclusive offerings in China, but also globally.

In April this year, Jiadong Health announced the launch of its fitness market business. Within just three months, it has integrated its T1 Pro Aerobic Capacity Assessment and Metabolic Monitoring Intelligent System, along with precision exercise health management technology, into more than 30 high-end fitness institutions across 13 cities in China, including Wales Fitness, Saipu Fitness, Qingbo Fitness, and Blue Bird Sports. This initiative has established an exercise guidance and training system based on metabolic and cardiopulmonary monitoring, completing the training and deployment for signed clients in the fitness market.

 Jiadong Health Holds Fitness Industry Launch Event in Shanghai

 Fitness Clubs Use the GetWell Smart System

In the healthcare sector, Jiadong Health has implemented a vertically integrated, in-depth strategy. In collaboration with thirteen Grade-A tertiary hospitals, it has established a clinical research framework for exercise assessment and precision exercise intervention targeting patients with diabetes of 1–5 years’ duration, achieving favorable clinical outcomes and earning high acclaim from numerous diabetes specialists. The next phase will expand this clinical collaboration on precision exercise intervention for diabetes to 50–100 hospitals. Meanwhile, Jiadong Health is pursuing FDA and NMPA (formerly CFDA) certifications and entering the commercial health examination and chronic disease management sectors to tap into the post-examination and rehabilitation markets. In the future, Jiadong Health will also conduct research and clinical applications of its products for cardiovascular and cerebrovascular diseases as well as postpartum persistent obesity.

Jiadong Health Holds International Clinical Cooperation Signing Ceremony

Regarding this financing round, Gong Yu, CEO of Jiadong Health, stated: “China is implementing the national strategy of ‘Healthy China.’ The nationwide fitness movement and the integration of sports and medicine are gaining strong momentum, while the health industry continues to expand in scale and attract significant interest from capital markets. Currently, approximately 360 million people in China regularly engage in physical exercise, forming a substantial consumer base. In terms of chronic diseases, there are over 100 million patients with diabetes and 290 million patients with cardiovascular and cerebrovascular diseases. These populations require targeted, effective, and safe exercise interventions; however, there are currently no deeply specialized vertical solutions available in the market.”

Adopting non-pharmacological approaches to health management is the core philosophy of Jiadong Health. As one of the few enterprises in China possessing core technologies in exercise and health, the company has accumulated years of research expertise in this field. Jiadong Health enters the health management sector through metabolic monitoring and precise exercise guidance, establishing a distinct market position with clear competitive advantages, and will continue to drive the development of China’s “exercise + health management” industry.

Earlier, Jiadong Health had already secured two rounds of investment from prominent investors and government-guided funds. The strategic investment from the CCB Zhongmin Medical Kunshan Fund will propel Jiadong Health’s transformation from a technology-leading company into a precision health management platform, empowering the entire broader health industry.

Getwell, established in late 2015, has set up its R&D and marketing center in Shenzhen, its research institute and operations center in Wuhu, and a scientific research and algorithm team in Canada. Adhering to the philosophy of “empowering everyone with precise health capabilities,” Getwell focuses on the research and application of artificial intelligence and next-generation metabolic monitoring in the field of sports and wellness. By integrating high-quality expert resources from both domestic and international markets, the company is committed to building a novel health service system centered on “exercise + nutrition” and creating a personalized, precision health management platform. This enables users to enhance the effectiveness and safety of their physical activities, thereby achieving scientific health management.

In the future, Jiadong Health will continue to focus on AI-driven health management, deepening its “core health data monitoring + AI” strategy. Leveraging its technological advantages and professional solutions, the company aims to unlock an unprecedented horizon of intelligent, precision health for both the industry and users.

CCB Zhongmin Healthcare Kunshan Fund is a privately offered fund under CCB International that operates on a market-oriented basis, focusing on investments in high-quality early- to growth-stage healthcare and medical enterprises. Leveraging the support of Kunshan High-Tech Industrial Development Zone, the fund capitalizes on CCB International’s synergistic advantages in investment banking and the expertise of its professional healthcare investment team, while integrating Zhongmin Future’s premium resources in the healthcare industry. It precisely selects technology commercialization projects within the healthcare sector, accelerates the development of innovative tech-driven healthcare companies, and is dedicated to providing comprehensive post-investment value-added services to portfolio companies, aiming to achieve shared growth and value creation with enterprises and shareholders.